Decisions about when to start or switch a therapy often depend on the frequency with which
individuals are monitored or tested. For example, the optimal time to switch antiretroviral …

Integrating artificial intelligence (AI) with SARS-CoV-2 diagnostics can help in the timely
execution of pandemic control and monitoring plans. To improve the efficiency of the …

HIV‐positive patients are at increased risk of developing chronic kidney disease. Although
guidelines recommend regular monitoring of renal function in individuals living with HIV, the …

Objective: To assess associations between engagement in-care and future mortality.
Design: UK-based observational cohort study. Methods: HIV-positive participants with more …

Objective: To illustrate an approach to compare CD4 cell count and HIV-RNA monitoring
strategies in HIV-positive individuals on antiretroviral therapy (ART). Design: Prospective …

Tremendous progress has been made with the scale-up of antiretroviral therapy in Africa,
with an estimated seven million people now receiving antiretroviral therapy in the region …

Objective: To evaluate the safety of in-utero exposure to atazanavir and neurodevelopment
in perinatally HIV-exposed but uninfected (PHEU) infants. Design: Prospective cohort study …

Background Chronic kidney disease is common in HIV positive patients and renal tubular
dysfunction has been reported in those receiving combination antiretroviral therapy (cART) …

Etravirine (Intelence®) is an orally administered next-generation non-nucleoside reverse
transcriptase inhibitor (NNRTI). It is approved for the treatment of HIV-1 infection in treatment …

Background Human Immunodeficiency virus type-1 (HIV) entry into target cells involves
binding of the viral envelope (Env) to CD4 and a coreceptor, mainly CCR5 or CXCR4. The …